Citi analyst Andrew Baum upgraded Merck to Buy from Neutral with a price target of $130, up from $105. The analyst "materially" increased estimates for Merck to reflect its novel antibody drug conjugates for cancer MK-2870/SKB-264 and cardiology agents sotatercept and MK-0616. Each 12 month delay to Keytruda biosimilars represents a 7% increase in net present value, the analyst tells investors in a research note. In addition, the company’s portfolio has little Inflation Reduction Act related pricing risk given the rare disease, animal health, and vaccines exposure, adds Citi.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck price target raised to $124 from $123 at Guggenheim
- Cantor biopharma/biotech analysts to hold an analyst/industry conference call
- Merck, Eisai colorectal cancer study did not meet statistical significance
- Merck, Eisai discontinuing Phase 3 melanoma combination study
- Moderna, Merck say mRNA cancer vaccine-KEYTRUDA combo granted PRIME designation